Basic Information
| LncRNA/CircRNA Name | TUSC7 |
| Synonyms | TUSC7, LINC00902, LSAMP-AS1, LSAMP-AS3, LSAMPAS3, NCRNA00295 |
| Region | GRCh38_3:116709235-116723581 |
| Ensemble | ENSG00000243197 |
| Refseq | NR_015391 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | CDDP and Taxol | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | endometrial cancer |
| ICD-0-3 | NA |
| Methods | qPCR |
| Sample | endometrial carcinoma tissues |
| Expression Pattern | down-regulated |
| Function Description | In this study, the low expression of TUSC7 was confirmed in endometrial carcinoma tissues and was associated with high pathological stages of endometrial carcinoma, which revealed that TUSC7 might be involved in tumorigenesis and progression of endometrial carcinoma. Moreover, the expression of TUSC7 in endometrial carcinoma tissues and cell lines resistant to CDDP and Taxol was lower than that in sensitive endometrial carcinoma tissues and cell lines, which indicated that the TUSC7 expression level was positively correlated with the response of endometrial carcinoma patients to chemotherapy with CDDP and Taxol. MiR-23b upregulation mostly reversed the TUSC7-induced regulatory effects on HEC1A/CR cell line. |
| Pubmed ID | 28653877 |
| Year | 2017 |
| Title | Long non-coding RNA tumor suppressor candidate 7 advances chemotherapy sensitivity of endometrial carcinoma through targeted silencing of miR-23b |
External Links
| Links for TUSC7 | GenBank HGNC NONCODE |
| Links for endometrial cancer | OMIM COSMIC |